Haverford Trust Co. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 937,667 shares of the biopharmaceutical company’s stock after buying an additional 31,060 shares during the period. Haverford Trust Co.’s holdings in Pfizer were worth $33,015,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. BlackRock Fund Advisors raised its position in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock valued at $2,741,378,000 after buying an additional 1,403,646 shares in the last quarter. Wellington Management Group LLP raised its stake in Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after buying an additional 3,936,078 shares in the last quarter. Franklin Resources Inc. raised its stake in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. BlackRock Group LTD raised its stake in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock valued at $1,762,838,000 after buying an additional 3,154,116 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Pfizer by 1.7% in the first quarter. Legal & General Group Plc now owns 29,385,795 shares of the biopharmaceutical company’s stock valued at $871,079,000 after buying an additional 488,194 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during mid-day trading on Friday, hitting $32.66. 15,569,339 shares of the company were exchanged. The company’s 50-day moving average is $34.02 and its 200 day moving average is $34.27. The company has a market capitalization of $198.10 billion, a P/E ratio of 28.95 and a beta of 0.86. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 earnings per share. Analysts expect that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.67%. Pfizer’s payout ratio is presently 95.24%.
A number of equities research analysts recently commented on the company. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target on the stock in a research report on Tuesday, August 2nd. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Piper Jaffray Cos. restated an “overweight” rating and set a $54.00 price target on shares of Pfizer in a research report on Monday, June 27th. BMO Capital Markets reaffirmed a “buy” rating and set a $40.00 price objective on shares of Pfizer in a report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. Eleven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.